China Universal Asset Management Co. Ltd. Grows Position in Grifols, S.A. (NASDAQ:GRFS)

China Universal Asset Management Co. Ltd. raised its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 63.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 23,464 shares of the biotechnology company’s stock after purchasing an additional 9,130 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Grifols were worth $208,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC increased its holdings in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 1,135 shares during the period. Signaturefd LLC raised its position in shares of Grifols by 66.2% in the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 2,153 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Grifols during the 2nd quarter worth $89,000. Creative Planning boosted its position in Grifols by 26.4% during the third quarter. Creative Planning now owns 17,319 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 3,614 shares in the last quarter. Finally, International Assets Investment Management LLC bought a new stake in Grifols during the third quarter valued at about $1,700,000.

Grifols Stock Performance

Shares of Grifols stock opened at $8.77 on Thursday. Grifols, S.A. has a one year low of $5.30 and a one year high of $12.15. The company has a market capitalization of $6.03 billion, a PE ratio of 8.68 and a beta of 0.50. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.80 and a current ratio of 1.68. The company has a 50-day simple moving average of $8.82 and a two-hundred day simple moving average of $7.77.

Grifols (NASDAQ:GRFS) last issued its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The firm had revenue of $1.96 billion during the quarter. Research analysts expect that Grifols, S.A. will post 0.79 EPS for the current fiscal year.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.